The DTWD2 Knockout K-562 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the chronic myeloid leukemia (CML) cell line K-562, engineered for loss-of-function studies of the DTWD2 gene. This knockout product consists of a heterogeneous pool of cells carrying diverse CRISPR-induced disruptions, providing a versatile tool to investigate DTWD2-dependent phenotypes without the biases of single-cell cloning. The polyclonal format preserves genetic diversity and allows for robust phenotypic screening in a leukemia-relevant background.
The K-562 cell line was originally established from the pleural effusion of a 53-year-old female patient with CML in blast crisis. K-562 cells are BCR-ABL1 positive and serve as a widely adopted model for blast crisis CML, capable of undergoing erythroid, granulocytic, and monocytic lineage differentiation under defined conditions. This unique differentiation plasticity, combined with the presence of the BCR-ABL1 oncogenic driver, makes K-562 an ideal host for examining how DTWD2 disruption influences leukemia cell fate and stress responses.
DTWD2 encodes a predicted RNA methyltransferase characterized by a DTW domain and is hypothesized to methylate transfer RNA (tRNA) substrates. By modifying tRNAs, DTWD2 modulates translation fidelity and efficiency. Loss of DTWD2 may cause tRNA hypomethylation, altering translation of specific transcripts and activating stress pathways. Downstream readouts include changes in global translation and increased eIF2?? phosphorylation, a key integrated stress response mediator. DTWD2 likely acts within a tRNA-modifying enzyme network, potentially interacting with methyltransferases TRMT61A and NSUN2. Its upstream regulators are undefined, but it contributes to translational regulation under homeostatic and stress conditions.
In the context of K-562 leukemia cells, DTWD2 disruption may impair tRNA modification and translational control, thereby perturbing oncogenic signaling and stress adaptation. Cancer cells frequently exhibit heightened protein synthesis and increased vulnerability to protetoxic stress, and this knockout model enables the dissection of how RNA modifications sustain leukemogenesis. The K-562 background, with its active BCR-ABL1 signaling and inherent differentiation capacity, offers a clinically relevant platform to assess the impact of DTWD2 loss on proliferation, apoptosis, and lineage-specific differentiation, potentially revealing novel vulnerabilities in CML blast crisis.
These polyclonal DTWD2 knockout cells are well suited for a broad range of experimental applications, including the functional characterization of orphan methyltransferases, quantitative analysis of tRNA modification by LC-MS/MS, and measurement of translational fidelity using puromycin incorporation assays. They can be employed in RNA sequencing studies to identify downstream transcriptomic changes, and in phospho-eIF2?? western blotting to monitor stress pathway activation. Additional uses include proliferation and apoptosis screening to support drug target validation and synthetic lethal interaction mapping with BCR-ABL1 inhibitors. For more information or to discuss custom gene editing needs, please contact Ascent Research.
